Radj Gervais

17.8k total citations · 3 hit papers
83 papers, 5.2k citations indexed

About

Radj Gervais is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Radj Gervais has authored 83 papers receiving a total of 5.2k indexed citations (citations by other indexed papers that have themselves been cited), including 63 papers in Pulmonary and Respiratory Medicine, 56 papers in Oncology and 11 papers in Molecular Biology. Recurrent topics in Radj Gervais's work include Lung Cancer Treatments and Mutations (53 papers), Lung Cancer Research Studies (32 papers) and Lung Cancer Diagnosis and Treatment (23 papers). Radj Gervais is often cited by papers focused on Lung Cancer Treatments and Mutations (53 papers), Lung Cancer Research Studies (32 papers) and Lung Cancer Diagnosis and Treatment (23 papers). Radj Gervais collaborates with scholars based in France, United States and Canada. Radj Gervais's co-authors include Frances A. Shepherd, Joachim von Pawel, Filippo de Marinis, Miklos Pless, Paolo Paoletti, Thomas Chang Yao Tsao, Paul A. Bunn, Christian Manegold, Sofia Paul and Thomas Müller and has published in prestigious journals such as The Lancet, JAMA and Journal of Clinical Oncology.

In The Last Decade

Radj Gervais

81 papers receiving 5.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy

2004 1.9k citations Radj Gervais et al. Journal of Clinical Oncology profile →
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial

2008 1.0k citations Radj Gervais et al. profile →
Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC

2021 201 citations Radj Gervais, Margarita Majem et al. Journal of Thoracic Oncology profile →

Peers

Countries citing papers authored by Radj Gervais

Since Specialization

Citations

This map shows the geographic impact of Radj Gervais's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Radj Gervais with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Radj Gervais more than expected).

Fields of papers citing papers by Radj Gervais

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Radj Gervais. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Radj Gervais. The network helps show where Radj Gervais may publish in the future.

Co-authorship network of co-authors of Radj Gervais

This figure shows the co-authorship network connecting the top 25 collaborators of Radj Gervais. A scholar is included among the top collaborators of Radj Gervais based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Radj Gervais. Radj Gervais is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Clinical characteristics and management of long survivors in extensive stage small cell lung cancer 2025 ·Lung Cancer ·Élisa Gobbini, Mamadou Diallo, Dominique Pasquier, Sophie C. Schneider, C. Chouaïd, D. Debieuvre, Xavier Quantin, Radj Gervais, Clarisse Audigier-Valette, (unknown), (unknown), Anne Madroszyk, Éric Pichon, (unknown), (unknown), Olivier Bylicki, (unknown), L. Bosquet, M. Pérol, Nicolas Girard	0
2	Validation of an anti-α-Gal IgE fluoroenzyme-immunoassay for the screening of patients at risk of severe anaphylaxis to cetuximab 2023 ·BMC Cancer ·(unknown), (unknown), Benoît Dupont, Bénédicte Clarisse, Jean‐Jacques Parienti, (unknown), (unknown), Yann Ollivier, Radj Gervais, Delphine Mariotte, Brigitte Le Mauff	3
3	Health-Related Quality of Life Impact from Adding Bevacizumab to Cisplatin-Pemetrexed in Malignant Pleural Mesothelioma in the MAPS IFCT-GFPC-0701 Phase III Trial 2019 ·Clinical Cancer Research ·Guillaume Eberst, Amélie Anota, Arnaud Scherpereel, Julien Mazières, J. Margery, Laurent Greillier, Clarisse Audigier-Valette, Denis Moro‐Sibilot, Olivier Molinier, H. Léna, F. Rivière, I. Monnet, V. Gounant, Henri Janicot, Radj Gervais, (unknown), (unknown), Franck Morin, Gérard Zalcman, Virginie Westeel	15
4	Phase II Study Evaluating the Mechanisms of Resistance on Tumor Tissue and Liquid Biopsy in Patients With EGFR-mutated Non-pretreated Advanced Lung Cancer Receiving Osimertinib Until and Beyond Radiologic Progression: The MELROSE Trial 2019 ·Clinical Lung Cancer ·Jaafar Bennouna, Nicolas Girard, Clarisse Audigier-Valette, Aurélie Le Thuaut, Radj Gervais, Philippe Masson, M. Marcq, Olivier Molinier, Alexis B. Cortot, D. Debieuvre, J. Cadranel, H. Léna, Denis Moro‐Sibilot, C. Chouaïd, B. Mennecier, T. Urban, Christine Sagan, (unknown), Fabrice Barlési, Marc G. Denis	19
5	Safety of combined PD‐1 pathway inhibition and radiation therapy for non‐small‐cell lung cancer: A multicentric retrospective study from the GFPC 2018 ·Cancer Medicine ·Paul Lesueur, Alexandre Escande, Juliette Thariat, (unknown), I. Monnet, Alexis B. Cortot, D. Lerouge, S. Danhier, Pascal Dô, Catherine Dubos‐Arvis, C. Chouaïd, Radj Gervais	36
6	Oxaliplatin-induced bronchiolitis obliterans organizing pneumonia following hyperthermic intraperitoneal chemotherapy 2018 ·Journal of Gastrointestinal Oncology ·Guillaume Le Baut, Jean‐Marc Guilloit, (unknown), Yann Ollivier, Catherine Dubos‐Arvis, Pascal Dô, (unknown), (unknown), Radj Gervais	1
7	Retrospective evaluation of concomitant cetuximab and radiotherapy tolerance for locoregional advanced head and neck squamous cell carcinoma treatment in patients unfit for platinum-based chemotherapy 2017 ·European Archives of Oto-Rhino-Laryngology ·(unknown), Radj Gervais, D. De Raucourt, E. Babin, Audrey Emmanuelle Dugué, (unknown), D. Blanchard, B. Géry	6
8	Identification of I1171N resistance mutation in ALK-positive non-small-cell lung cancer tumor sample and circulating tumor DNA 2016 ·Lung Cancer ·Alison Johnson, Pascal Dô, Nicolas Richard, Cathérine Dubos, Jean Jacques Michels, Jessica Bonneau, Radj Gervais	8
9	Successful treatment with ceritinib after crizotinib induced hepatitis 2016 ·Lung Cancer ·Marion Sassier, B. Mennecier, (unknown), (unknown), Antoine Coquerel, Xavier Humbert, Joachim Alexandre, Sophie Fédrizzi, Radj Gervais	12
10	The Impact of EGFR T790M Mutations and BIM mRNA Expression on Outcome in Patients with EGFR -Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial 2014 ·Clinical Cancer Research ·Carlota Costa, Miguel Angel Molina, Ana Drozdowskyj, Ana Giménez‐Capitán, Jordi Bertrán-Alamillo, Niki Karachaliou, Radj Gervais, Bartomeu Massutí, Jia Wei, Teresa Morán, Margarita Majem, Enriqueta Felip, Enric Carcereny, Rosario García‐Campelo, Santiago Viteri, Miquel Tarón, Mayumi Ono, Petros Giannikopoulos, Trever G. Bivona, Rafael Rosell	180
11	Cancer de l’oropharynx 2014 ·Bulletin du Cancer ·D. Blanchard, Jean-Pierre Rame, (unknown), B. Géry, (unknown), D. De Raucourt, Radj Gervais	5
12	Harmonizing SUVs in multicentre trials when using different generation PET systems: prospective validation in non-small cell lung cancer patients 2013 ·European Journal of Nuclear Medicine and Molecular Imaging ·Charline Lasnon, Cédric Desmonts, Elske Quak, Radj Gervais, Pascal Dô, Catherine Dubos‐Arvis, Nicolas Aide	88
13	Does Bilobectomy Offer Satisfactory Long-Term Survival Outcome for Non-Small Cell Lung Cancer? 2013 ·The Annals of Thoracic Surgery ·Philippe Icard, (unknown), Françoise Galateau-Sallé, P Rosat, (unknown), Radj Gervais, Gérard Zalcman, Jean‐Luc Hanouz	5
14	Randomized, Phase III Study of Gemcitabine or Erlotinib Maintenance Therapy Versus Observation, With Predefined Second-Line Treatment, After Cisplatin-Gemcitabine Induction Chemotherapy in Advanced Non–Small-Cell Lung Cancer 2012 ·Journal of Clinical Oncology ·M. Pérol, C. Chouaïd, David Pérol, Fabrice Barlési, Radj Gervais, Virginie Westeel, Jacky Créquit, H. Léna, A. Vergnenègre, Gérard Zalcman, I. Monnet, H. Le Caer, P. Fournel, L. Falchero, M. Poudenx, F. Vaylet, Céline Ségura‐Ferlay, Mojgan Devouassoux‐Shisheboran, Miquel Tarón, B. Milleron	166
15	Anti-cetuximab IgE ELISA for identification of patients at a high risk of cetuximab-induced anaphylaxis 2011 ·mAbs ·Delphine Mariotte, Benoît Dupont, Radj Gervais, Marie‐Pierre Galais, D. Laroche, (unknown), E. Comby, Karine Bouhier‐Leporrier, Jean‐Marie Reimund, Brigitte Le Mauff	41
16	Randomized Multicenter Phase II Study of Larotaxel (XRP9881) in Combination with Cisplatin or Gemcitabine as First-Line Chemotherapy in Nonirradiable Stage IIIB or Stage IV Non-small Cell Lung Cancer 2008 ·Journal of Thoracic Oncology ·Petr Zatloukal, Radj Gervais, Johan Vansteenkiste, Leon Bosquée, C. Sessa, Étienne Brain, Éric Dansin, T. Urban, Nadine Dohollou, M Besenval, Élisabeth Quoix	22
17	Phase III Double-Blind, Placebo-Controlled Study of Thalidomide in Extensive-Disease Small-Cell Lung Cancer After Response to Chemotherapy: An Intergroup Study FNCLCC cleo04–IFCT 00-01 2007 ·Journal of Clinical Oncology ·Jean Louis Pujol, (unknown), Radj Gervais, Marie‐Laure Tanguy, Élisabeth Quoix, Philippe David, Henri Janicot, Virginie Westeel, (unknown), Jean Genève, D Maraninchi	97
18	A randomised phase II study of the efficacy and safety of intravenous topotecan in combination with either cisplatin or etoposide in patients with untreated extensive disease small-cell lung cancer 2005 ·Lung Cancer ·Élisabeth Quoix, Jean-Luc Breton, Radj Gervais, (unknown), Franz M.N.H. Schramel, Felipe Cardenal, Graham Ross, A. Preston, (unknown), K. Mattson	21
19	Stent placement in superior vena cava syndrome 2003 ·The Annals of Thoracic Surgery ·P. Courthéoux, Barbara Alkofer, (unknown), Radj Gervais, (unknown), Philippe Icard	30
20	Congenital bilateral absence of the vas deferens (CBAVD) and cystic fibrosis transmembrane regulator (CFTR): correlation between genotype and phenotype 1996 ·Human Genetics ·Viviane Dumur, Radj Gervais, (unknown), (unknown), (unknown), Jean‐Jacques Lafitte, Philippe Roussel	71

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact